MUMBAI, India and WARREN, N.J., April 3, 2026
Cipla USA Inc., a subsidiary of Cipla Limited, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules (100 mg and 150 mg), indicated for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and life-threatening lung disease. The approval marks a significant expansion of Cipla’s U.S. respiratory portfolio, with the company announcing plans for an immediate commercial launch, reinforcing its commitment to improving access to high-quality, cost-effective therapies in complex disease areas.
FDA Approval Strengthens Respiratory Portfolio
The FDA approval of generic Nintedanib Capsules represents a strategic milestone for Cipla as it continues to strengthen its position in the respiratory therapeutics market, particularly in the United States, one of the most competitive and regulated pharmaceutical landscapes globally. The approved product is the generic therapeutic equivalent of Ofev®, originally developed and marketed by Boehringer Ingelheim, and is expected to provide a more affordable treatment option for patients suffering from idiopathic pulmonary fibrosis.
With immediate launch readiness and a robust supply chain strategy, Cipla aims to ensure consistent availability across specialty pharmacy distribution channels, addressing both patient demand and healthcare system needs. The approval also underscores the company’s capabilities in developing complex generics under stringent regulatory standards, aligning with its broader strategy of expanding its footprint in regulated global markets.
Addressing High Burden of Idiopathic Pulmonary Fibrosis
Advertisement
Idiopathic pulmonary fibrosis (IPF) is a severe and progressive interstitial lung disease characterized by irreversible scarring (fibrosis) of lung tissue, leading to declining lung function, reduced oxygen exchange, and ultimately respiratory failure. Patients with IPF often experience worsening shortness of breath, chronic cough, and significant deterioration in quality of life, with limited treatment options available to slow disease progression. Nintedanib, a tyrosine kinase inhibitor, works by targeting pathways involved in fibrosis and disease progression, helping to slow the rate of lung function decline.
The availability of a generic version is expected to significantly improve treatment accessibility, particularly for patients facing high costs associated with branded therapies. Given that the reference product generated approximately $3.76 billion in U.S. sales (IQVIA MAT January 2026), the introduction of a cost-effective alternative is likely to have a substantial impact on patient access and healthcare affordability.
Market Impact and Strategic Growth Opportunity
The approval of Cipla’s Nintedanib Capsules aligns with the company’s long-term strategy of focusing on complex generics and specialty pharmaceuticals, particularly in high-value therapeutic areas such as respiratory diseases, oncology, and anti-infectives. Cipla’s global presence, with over 46 manufacturing sites and operations across 80+ markets, positions it well to scale production and distribution efficiently. The company’s strong track record in delivering affordable medicines, including its historic contributions to HIV/AIDS treatment accessibility, reinforces its reputation as a patient-centric pharmaceutical leader.
By entering the IPF treatment market, Cipla not only expands its respiratory franchise but also strengthens its competitive positioning in a segment characterized by high unmet need and growing demand for innovative and accessible therapies. The launch is expected to enhance market competition, potentially driving down treatment costs while maintaining high standards of quality and regulatory compliance.
With this approval, Cipla advances its mission of improving global healthcare access, delivering a critical therapy for a debilitating lung disease, and reinforcing its role as a key player in the evolving pharmaceutical landscape, where innovation, affordability, and regulatory excellence remain central to patient care.
Source: Cipla press release
